• New study shows that rate of patient persistence using Sandoz AirFluSal® Forspiro® is twice as high as for reference product Seretide® Diskus®
• Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases
• Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD
Chippenham, UK – 31 August 2016: Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading inhaled airways disease focused business, confirms the announcement made by its partner Novartis, that new data just published in a leading medical journal, shows for the first time that the rate of treatment persistence for patients using the innovative Sandoz AirFluSal® Forspiro® respiratory inhaler is more than twice as high as for the reference product.
The results are reported in the latest edition of the leading Journal of Allergy and Clinical Immunology: In Practice. The comparative analysis study is the largest European Real-World Evidence (RWE) study ever conducted in asthma and COPD (chronic obstructive pulmonary disease).
The study, entitled “Comparative analysis of persistence to treatment among patients with asthma or COPD receiving AirFluSal® Forspiro® or Seretide® Diskus® salmeterol / fluticasone propionate combination therapy”, concluded that patients using the Sandoz device showed a persistence rate of 22.9%, compared to 10.5% for those using the reference product device.
The study was designed to retrospectively analyse persistence rates between the two devices, using dispensing datas from a large German pharmacy database. While retrospective database analyses have some limitations, the strengths of this data include the fact that 11,744 patients were included in a matched pair analysis, controlled for gender, age and month of treatment initiation (to limit seasonal effects).
¬¬All patients were first time users of salmeterol/fluticasone propionate and persistence to treat was analysed for a 12 month period.
AirFluSal Forspiro has been launched to date in approximately 30 countries, in Europe and elsewhere.
James Ward-Lilley, Vectura’s CEO commented:
"This announcement is further validation of our expertise in the development of inhaled respiratory products. In order to improve patient experience with inhalation devices, Sandoz and Vectura collaborated closely with patients during the development process. The device includes multiple feedback mechanisms such as visual control features, which help reassure the patient about dosing and a simple lever arm to load the dose.”
[1] Seretide® and Diskus® are registered trademarks owned by Glaxo Group Ltd.
• Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases
• Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD
Chippenham, UK – 31 August 2016: Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading inhaled airways disease focused business, confirms the announcement made by its partner Novartis, that new data just published in a leading medical journal, shows for the first time that the rate of treatment persistence for patients using the innovative Sandoz AirFluSal® Forspiro® respiratory inhaler is more than twice as high as for the reference product.
The results are reported in the latest edition of the leading Journal of Allergy and Clinical Immunology: In Practice. The comparative analysis study is the largest European Real-World Evidence (RWE) study ever conducted in asthma and COPD (chronic obstructive pulmonary disease).
The study, entitled “Comparative analysis of persistence to treatment among patients with asthma or COPD receiving AirFluSal® Forspiro® or Seretide® Diskus® salmeterol / fluticasone propionate combination therapy”, concluded that patients using the Sandoz device showed a persistence rate of 22.9%, compared to 10.5% for those using the reference product device.
The study was designed to retrospectively analyse persistence rates between the two devices, using dispensing datas from a large German pharmacy database. While retrospective database analyses have some limitations, the strengths of this data include the fact that 11,744 patients were included in a matched pair analysis, controlled for gender, age and month of treatment initiation (to limit seasonal effects).
¬¬All patients were first time users of salmeterol/fluticasone propionate and persistence to treat was analysed for a 12 month period.
AirFluSal Forspiro has been launched to date in approximately 30 countries, in Europe and elsewhere.
James Ward-Lilley, Vectura’s CEO commented:
"This announcement is further validation of our expertise in the development of inhaled respiratory products. In order to improve patient experience with inhalation devices, Sandoz and Vectura collaborated closely with patients during the development process. The device includes multiple feedback mechanisms such as visual control features, which help reassure the patient about dosing and a simple lever arm to load the dose.”
[1] Seretide® and Diskus® are registered trademarks owned by Glaxo Group Ltd.
